The research highlights the efficacy of liquid biopsy in diagnosing and surveilling HPV-associated oropharyngeal cancer. The study conducted by Ferrandino and colleagues evaluated a commercially available blood test's performance in identifying tumor tissue-modified viral-HPV DNA. The test demonstrated 100% specificity for diagnosing oropharyngeal cancer and surveillance for recurrence, with a sensitivity of 91.5% for disease identification and 88.4% for surveillance. The study emphasizes the importance of further clinical workup despite negative results in high clinical suspicion cases. Liquid biopsy shows promise in transforming the identification and monitoring of HPV-related diseases, but more validation studies are needed for widespread clinical use.
To Another Language
from source content
www.medscape.com
Key Insights Distilled From
by Megan Brooks at www.medscape.com 07-17-2023
https://www.medscape.com/viewarticle/994418Deeper Inquiries